Next‐generation sequencing in two cases of de novo acute basophilic leukaemia

• Published in: Journal of cellular and molecular medicine Vol. 25; no. 14; pp. 7095 - 7099
• Main Authors: Shimizu, Takuya, Kondo, Tadakazu, Nannya, Yasuhito, Watanabe, Mizuki, Kitawaki, Toshio, Shindo, Takero, Hishizawa, Masakatsu, Yamashita, Kouhei, Ogawa, Seishi, Takaori‐Kondo, Akifumi
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.07.2021; John Wiley and Sons Inc
• Subjects: acute basophilic leukaemia; Acute myeloid leukemia; Aged; Antigens, CD34 - genetics; Antigens, CD34 - metabolism; Basophils - metabolism; Basophils - pathology; Bone marrow; CD123 antigen; CD34 antigen; Chemotherapy; Dioxygenases - genetics; DNA-Binding Proteins - genetics; Epigenetics; Fever; Flow cytometry; gemtuzumab ozogamicin; Heterozygosity; High-Throughput Nucleotide Sequencing; Histamine; Humans; Hypotension; Interleukin-3 Receptor alpha Subunit - genetics; Interleukin-3 Receptor alpha Subunit - metabolism; Leukemia; Leukemia, Basophilic, Acute - genetics; Leukemia, Basophilic, Acute - pathology; Leukocytes (basophilic); Loss of heterozygosity; Male; Microscopy; Middle Aged; Monoclonal antibodies; Morphology; Mutation; next‐generation sequencing; Nucleophosmin - genetics; p53 Protein; Proto-Oncogene Proteins c-kit - genetics; Proto-Oncogene Proteins c-kit - metabolism; Sequence Analysis, DNA; Short Communication; Short Communications; Tumor Suppressor Protein p53 - genetics; next-generation sequencing; acute basophilic leukaemia; gemtuzumab ozogamicin
• ISSN: 1582-1838; 1582-4934; 1582-4934
• DOI: 10.1111/jcmm.16591

Acute basophilic leukaemia (ABL) is a rare subtype of acute myeloid leukaemia (AML); therefore, few data are available about its biology. Herein, we analysed two ABL patients using flow cytometry and next‐generation sequencing (NGS). Two cell populations were detected by flow cytometry in both patients. In Case no. 1, blasts (CD34+, CD203c−, CD117+, CD123dim+) and basophils (CD34−, CD203c+, CD117±, CD123+) were identified, both of which were found by NGS to harbour the 17p deletion and have loss of heterozygosity of TP53. In Case no. 2, blasts (CD33+, CD34+, CD123−) and basophils (CD33+, CD34+, CD123+) were identified. NGS detected NPM1 mutations in either blasts or basophils, and TET2 in both. These data suggest an overlap of the mutational landscape of ABL and AML, including TP53 and TET2 mutations. Moreover, additional mutations or epigenetic factors may contribute for the differentiation into basophilic blasts.